



Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts

Nicolas Girerd, Christophe Leclercq, Olivier Hanon, Antoni Bayés-Genís, James L Januzzi, Thibaut Damy, Benoit Lequeux, Christophe Meune, Pierre Sabouret, François Roubille

► To cite this version:

Nicolas Girerd, Christophe Leclercq, Olivier Hanon, Antoni Bayés-Genís, James L Januzzi, et al.. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts. *Revista Española de Cardiología (English version)*, 2023, 76 (10), pp.813-820. 10.1016/j.rec.2023.03.005 . hal-04029734

HAL Id: hal-04029734

<https://hal.univ-lorraine.fr/hal-04029734>

Submitted on 15 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts

Optimización de los tratamientos de la insuficiencia cardiaca con fracción de eyección reducida en la práctica diaria: propuesta de un grupo de expertos

Nicolas GIRERD,^a Christophe LECLERCQ,^b Olivier HANON,^c Antoni BAYES-GENIS,^d James L JANUZZI,^f Thibaut DAMY,^g Benoit LEQUEUX,^h Christophe MEUNE,ⁱ Pierre SABOURET,^j and François ROUBILLE^k

^a Université de Lorraine, INSERM, Centre d'Investigations Cliniques-Plurithématique 14-33, CHRU Nancy, and INSERM U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

^b CHU Rennes, Université Rennes 1, RENNES, France; LTSI Inserm U642, CIC-IT, 804, RENNES, France

^c Université de Paris Cité, EA 4468, F-75013, Paris, France, AP-HP, Service de Gériatrie, Hôpitaux Universitaires Paris Centre, Gérotopôle d'Île-de-France, PARIS, France.

^d Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

^e Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain

^f Massachusetts General Hospital, Harvard Medical School, and the Baim Institute for Clinical Research, Boston Massachusetts, United States.

^g Service de cardiologie, CHU Henri Mondor AP-HP, Creteil, France

^h Service de cardiologie, CHU Poitiers, Poitiers, France

ⁱ Service de cardiologie, CHU Avicenne, Université Paris 13, Bobigny, France.

^j Institut de Cardiologie, Service de cardiologie, CHU La Pitié Salpêtrière, Sorbonne Université, Paris, France.

^k PhyMedExp, Service de Cardiologie, Université de Montpellier, INSERM U1046, CNRS UMR 9214, INI-CRT, Montpellier, France.

* Corresponding author.

E-mail address: **nicolas_girerd@yahoo.com**

Twitter: @NicolasGirerd

ABSTRACT

Although treatment of patients with heart failure with reduced ejection fraction (HFrEF) with a combination of 4 medication classes is now recommended in major international practice guidelines, these guidelines do not specify how these treatments should be introduced and up-titrated. In consequence, many patients with HFrEF do not move on to an optimised treatment regimen. The objective of this review is to propose a pragmatic algorithm for treatment optimisation designed to be as easy as possible for practicing physicians to apply in routine practice. The first treatment goal is to ensure that all 4 recommended classes of medication are initiated as early as possible, in order to establish effective therapy, even at a low dose. This is considered preferable to starting fewer medications at a maximal dose. The second goal is to ensure that the intervals between introduction of different medications and between different titration steps are as short as possible, consistent with ensuring the safety of the patient. Specific proposals are made for older patients (> 75 years) who are frail, and for those with cardiac rhythm disorders. Application of this algorithm should allow an optimal treatment protocol to be achieved within a 2-month time-frame in the vast majority of patients. This needs to be our treatment goal in HFrEF and every effort must be undertaken to achieve it.

Keywords:

Heart failure

Treatment optimisation

Titration

Practice guidelines treatment algorithm

Cardiovascular diseases

RESUMEN

El tratamiento de los pacientes con insuficiencia cardiaca con fracción de eyección reducida (IC-FEr) con una combinación de cuatro clases de fármacos se recomienda actualmente en las principales guías de práctica clínica internacionales. Sin embargo, estas guías no especifican cómo deben introducirse y ajustarse estos tratamientos. En consecuencia, muchos pacientes con IC-FEr no pasan a un régimen de tratamiento optimizado. El objetivo de esta revisión es proponer un algoritmo pragmático para optimizar el tratamiento, diseñado para que sea lo más fácil posible de aplicar en la práctica diaria. El primer objetivo del tratamiento es garantizar que las cuatro clases de medicación recomendadas se inicien lo antes posible, con el fin de establecer una terapia eficaz, incluso a dosis bajas. Esto se considera preferible a iniciar menos medicamentos a una dosis máxima. El segundo objetivo es garantizar que los intervalos entre la introducción de los distintos medicamentos y entre los distintos pasos de titulación sean lo más breves posible, en consonancia con la seguridad del paciente. Se hacen propuestas específicas para los pacientes de edad avanzada (> 75 años) que son frágiles, y para aquellos con trastornos del ritmo cardiaco. La aplicación de este algoritmo debería permitir alcanzar un protocolo de tratamiento óptimo en un plazo de 2 meses en la gran mayoría de los pacientes. Este debe ser nuestro objetivo en el tratamiento de la IC-FEr y debemos hacer todo lo posible por conseguirlo.

Palabras clave:

Insuficiencia cardiaca

Optimización del tratamiento

Titulación

Algoritmo de tratamiento de guías de práctica clínica

Enfermedades cardiovasculares

ABBREVIATIONS

HF: heart failure

BB: beta-blockers

ARNI: angiotensin receptor-neprilysin inhibitors

ACEI: angiotensin-converting enzyme inhibitors

MRI: mineralocorticosteroid receptor antagonist

SGTL2I: type 2 sodium-glucose cotransporter inhibitor

GDMT: guideline-directed medical therapy

ABREVIATURAS

IC: insuficiencia cardiaca

BB: bloqueadores beta

ARNI: inhibidores del receptor la angiotensina y de la neprilisina

IECA: inhibidores de la enzima de conversión de la angiotensina

ARM: antagonistas del receptor de mineralocorticoides

ISGTL2: inhibidores del cotransportador de sodio-glucosa tipo 2

GDMT: guideline-directed medical therapy

INTRODUCTION

Heart failure (HF) is a major cause of hospitalisation, morbidity and mortality, notably in older patients, with an estimated worldwide prevalence of around 2%.¹ Nonetheless, appropriate management effectively prevents disease aggravation, acute decompensations and saves lives,² although optimisation is rarely obtained in real-life. New international practice guidelines have been published recently,^{3,4} which recommend the use of a combination of 4 medication classes as the platform therapy for HF with reduced ejection fraction (Class I recommendation). These are certain beta-blockers (BB), angiotensin receptor-neprilysin inhibitors (ARNIs) or angiotensin-converting enzyme inhibitors (ACEIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2Is). However, how to introduce such guideline-directed medical therapy (GDMT) in a given patient remains a matter of debate.⁵⁻¹²

Important factors limiting the introduction and titration of HF medications include worsening renal function,¹³ low blood pressure¹⁴ and low heart rate.¹⁵ Concomitant initiation of multiple drugs which carry a risk of these adverse events can be a hurdle, and this needs to be considered when choosing a therapeutic strategy. Likewise, rapid treatment optimisation, ideally within a 2-month timeframe, is also a challenge.

In the present article, we propose a pragmatic approach designed to be as easy as possible for practicing physicians to apply in routine practice. We have tried to take into consideration recent guidelines, the notion of early implementation and its difficulties, and the need to tailor management to individual patient requirements. This position statement was prepared through a collaboration between experts from the Heart Failure Working Group of the French Society of Cardiology, with the aims of promoting treatment optimisation and facilitating the practical implementation of the ESC HF guidelines.⁴

FACTORS TO CONSIDER WHEN DESIGNING AN ALGORITHM FOR MEDICATION OPTIMISATION IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

Pharmacological considerations

The different classes of GDMT target different pathophysiological mechanisms: ARNIs/ACEI and MRAs inhibit the renin-angiotensin-aldosterone system,¹⁶ with ARNIs also specifically blocking the degradation of natriuretic peptides and other vasoactive hormones.¹⁷ BBs principally target the autonomic nervous system, but also inhibit renin synthesis.¹⁸ Finally, SGLT2Is were originally developed to prevent glucose and sodium reabsorption in the kidney, but their beneficial effects in HF probably involve extrarenal mechanisms which are not yet fully elucidated.¹⁹ From a pharmacological perspective, it appears reasonable to target the maximum number of physiopathological mechanisms in parallel, rather than attempting to achieve maximal inhibition of a single pathway.

Efficacy considerations

Historically, classes of GDMT were introduced sequentially, following demonstration of their efficacy from well-designed randomized clinical trials spanning a period of over thirty years. For this reason, each novel class has usually been evaluated compared to placebo over a platform therapy of previously available medication, and direct head-to-head comparative studies have not been performed (except for ARNIs vs ACEIs).²⁰

To address the limited amount of data from direct comparisons, the relative efficacy of different HF treatments has been addressed in a recent metaanalysis of 75 randomized clinical trials.²¹ Unsurprisingly, the most effective option in reducing all-cause death relative to placebo was the concomitant use of an ARNI, a BB, a MRA and a SGLT2I.²¹ Importantly, there is no evidence for

interactions between classes of HF medication and the available data strongly suggest that each class has an independent impact on clinical outcomes, regardless of the other drugs with which the patient is treated.^{8,22}

As well as the absolute treatment effect sizes of the different medication classes, the order in which they are introduced may also be important. For example, in a recent study in which different treatment sequences were modelled using data from 6 pivotal trials,¹⁰ some differences in mortality outcomes were observed between sequences. However, the most important factor in reducing mortality was the rapidity of treatment up-titration.¹⁰

Early introduction of therapy following diagnosis or an acute exacerbation is recommended to optimise the prognosis. *Post hoc* findings from recent trials have consistently demonstrated a rapid reduction of risk following initiation of therapy. For example, in a large randomised trial comparing sacubitril/valsartan to enalapril,²⁰ and in recent trials of SGLT2i,^{23,24} rehospitalizations were significantly reduced within 1 month of treatment initiation. Recently, in the STRONG-HF trial,²⁵ 900 hospitalised patients were randomised to management either with 'usual care' or 'high-intensity care'. The latter group received rapidly up-titrated 4-drug therapy to achieve optimal doses within 2 weeks of discharge. This approach was feasible and safe, and the trial demonstrated that rapid-titration of GDMT significantly reduced the risk of 180-day all-cause death or HF hospitalisation.²⁵ Acute hospitalisations provide a window of opportunity to initiate and optimise treatments for HF, and this window of opportunity will be lost if patients are discharged untreated.

Safety considerations

Low blood pressure, low heart rate, impairment of renal function and electrolyte disturbances, principally hyperkalaemia with MRAs, are the principal adverse events which limit the optimisation of GDMT.²⁶ In this respect, SGLT2Is appear to have the best safety profile as their effect on blood pressure is minimal and they do not generally cause orthostatic hypotension in those without hyperglycaemia (which can easily be rectified with intensification of other treatments for diabetes).²⁷

However, SGLT2Is may expose patients to a higher risk of ketoacidosis,²⁸ especially if the patient becomes haemodynamically unstable and goes into shock. In such cases, SGLT2I treatment should be delayed or discontinued.²⁷ These drugs also may increase the risk of urinary infections in patients with a urinary catheter in place.²⁸

Low blood pressure is principally an issue for BBs, ACEIs and ARNIs. Impaired renal function, due to reversible hemodynamic effects, is observed with MRAs, ACEIs and ARNIs.^{13,29} While SGLT2I treatment may lead to a small early rise in serum creatinine, these drugs provide significant renal protection in the mid-term.¹³ It should be noted that little information is available on medication risk in patients with very severe HF (ejection fraction < 25%), and these may require more conservative management. Of note, difficulties related to low blood pressure and impairment of renal function can be attenuated with recently proposed management algorithms.^{14,29}

Another factor that influences how quickly GDMT can be optimised is persistence of congestion, which is associated with poor prognosis after discharge.³⁰ Apart from BB, which may need to be introduced later or titrated more slowly, persistent congestion should not prevent optimisation of GDMT prior to discharge. Indeed, ACEIs, ARNIs and SGLT2Is have been shown to improve decongestion.³¹⁻³³ However, the question of managing congestion is a complex one and deserves lengthier treatment elsewhere.

Comorbidities

Comorbidities are frequent in HF, especially diabetes, chronic respiratory diseases, and chronic kidney disease.¹ Many of the medications used for the treatment of HF are also effective in these other conditions or diseases such as hypertension or longstanding coronary artery disease. In patients with diabetes, the use of SGLT2Is in HF may improve glycaemic control as well as improving cardiac function. This class of drug has also more recently been shown to reduce disease progression and mortality in patients with chronic kidney disease.³⁴ Moreover, ARNIs have also been shown to improve diabetes control³⁵ and renal function in patients with HF.

PROPOSED ALGORITHM FOR OPTIMISATION OF HEART FAILURE MEDICATION

On the basis of the available evidence, we propose an algorithm for the initiation or optimisation of treatments for HF (figure 1). Our goal is to provide a simplified approach to the heterogeneous clinical presentations of patients, focusing on key factors that may influence drug tolerability (figure 2). The algorithm proposed can be applied to most patients. However, we appreciate that there are other patient groups whose clinical presentations are more complex. Our algorithm may be adapted in these cases for a more sophisticated comorbidity-based approach.³⁶ It should be noted that we focus here on a practical approach to optimise GDMT, and do not discuss other important aspects of HF management, such as second-line treatments, non-pharmacological management, and management of comorbidities.

The underlying principles of this algorithm (figure 2) are the following:

- a) To ensure that all 4 recommended classes of GDMT are initiated as early as possible, in order to establish effective therapy, even at a low dose. This is considered preferable to starting fewer medications at a maximal dose, and has been identified as the most effective strategy in the network metaanalysis.²¹
- b) To ensure that the intervals between introduction of different medications and between different titration steps are as short as possible, consistent with ensuring the safety of the patient. Again, rapid titration has been shown to provide mortality benefits in the STRONG-HF trial.²⁵
- c) To ensure that the time from first treatment initiation to reaching the target dose for all 4 GDMT components⁴ does not exceed 30 days and that the patient is stabilised on optimal medication dosing within 2 months.

The algorithm proposed is a general one, developed for use in all patients with HF, except for 2 specific populations who may require different treatment strategies. The needs of these patients are addressed separately below. This concerns:

a) Patients aged > 75 years who are frail (defined as a Triage Risk Screening Tool score ≥ 2)^{37,38}

b) Patients with certain cardiac rhythm disorders

The algorithm proposes specific management pathways depending on the number of current HF medication classes used, on whether the patient is hospitalised or not, and on the presence of low blood pressure (systolic blood pressure < 100 mm Hg) or impaired renal function (estimated glomerular filtration rates [eGFR] < 30 ml/min/1.72 m²).

Management of patients aged > 75 years

The prevalence of HF rises steeply with age, reaching between 15% and 20% in individuals aged ≥ 80 years.³⁹ These patients are more likely to develop adverse events to medication, are likely to be already polymedicated, and to present unfavorable prognostic factors, such as renal failure, cognitive disorders, a risk of falls and malnutrition. These considerations need to be considered when deciding how to optimize treatment in such patients. Moreover, frailty is very common in older people with HF (45%)⁴⁰ and this increases the risk of mortality and hospitalisations.⁴¹

All patients aged > 75 years should undergo frailty evaluation using validated frailty scales. We recommend using the Triage Risk Screening Tool (TRST),³⁸ which is a very simple and rapid test considering multiple dimensions of frailty. Recently a Cardiology/Geriatrics consensus group proposed using the TRST as a frailty screening tool in the cardiology setting.³⁷ Patients with a TRST score ≥ 2 should be considered frail and treated in a more conservative manner. However, others frailty scales can also be used, including the FRAIL scale,⁴² the Clinical Frailty Score,⁴³ or the Fried criteria,⁴⁴ although these scales cover less dimensions of frailty than the TRST.

For the frail patients, treatment escalation should be more gradual than that proposed in the general HF treatment algorithm. Starting doses of all drug classes should be $\frac{1}{4}$ the full dose, with the

exception of SGLT2Is, which can be given at the full dose. The dosing interval should be extended to 1-2 weeks between each change in medication and the dose increased in incremental steps of a ¼ dose. The final dose of all medications will more often be below the usual targets specified in treatment guidelines for all drugs, apart from SGLT2Is. Nonetheless, titration to maximally tolerated doses in the elderly should be attempted whenever possible. An algorithm illustrating the proposed treatment escalation sequences for frail patients > 75 years old according to their baseline blood pressure and kidney function status is provided in figure 3.

In addition, the presence of frailty should trigger the management of comorbidities and geriatric syndromes by a comprehensive geriatric assessment.^{37,45} This multidimensional assessment should take into account comorbidities, cognitive function, autonomy, walking disorders, the risk of falls, nutritional status, depression, polypharmacy, vaccination status (notably influenza, pneumococcus and COVID) and social isolation.^{37,45} Such multidisciplinary management has been shown to reduce mortality in older patients with HF.⁴⁵ Any medical needs identified during this assessment should be addressed promptly in parallel to HF treatment. Wherever appropriate, specific comorbidities should be managed, home help (nurses and social support) and cognitive stimulation offered, physical activity adapted, and physiotherapy or psychotherapy provided as needed. Medications and vaccination status should be checked, and vitamin D supplementation, oral nutritional supplements and antidepressant treatment provided when justified. Finally, an environmental assessment should be made.

Management of patients with cardiac rhythm disorders

Cardiac rhythm disturbances, such as supraventricular and ventricular arrhythmias, bradycardia and conduction disturbances (mainly left-bundle branch block) are commonly observed in patients with HF, and contribute to the increased mortality and morbidity of these patients.⁴ For these reasons, it

is important to ensure a specific diagnostic work-up for rhythm disorders and their appropriate management in all patients diagnosed with HF. Associated rhythm disorders can have an impact on the titration strategy, as in patients with ventricular tachycardia or premature ventricular contractions, BB should be introduced in the first treatment step, in preference to ACEIs or ARNIs, due to their beneficial effect on rate control.

In addition, the decision to implant a cardioverter-defibrillator should be made after drug optimization, according to ESC practice guidelines,⁴ in all patients with symptomatic HF (NHYA class II-III) and a left ventricular ejection fraction $\leq 35\%$ with ischemic cardiomyopathy (Class IA recommendation) and non-ischemic cardiomyopathy (Class IIa A). Rapid initiation of HF drugs is advisable to ensure timely implementation of cardioverter-defibrillators in patients in whom left ventricular ejection fraction remains $\leq 35\%$. In patients with HF and wide QRS and conduction disorders, cardiac resynchronization therapy should be considered, the level of recommendations depending on the QRS width and the type of conduction disorder (presence or absence of left-bundle branch block).⁴

Atrial fibrillation (AF) is a common comorbidity in patients with HF, its prevalence increasing with the severity of HF.⁴⁶ Around half of all patients with HF either have pre-existing AF at the time of diagnosis of HF or develop AF subsequently.⁴⁷ Comorbid AF may aggravate underlying HF,⁴⁸ for example due to the development of tachycardia-mediated cardiomyopathy which impairs ventricular contractility.⁴⁶ Patients with AF should be proposed cardioversion and antiarrhythmic drugs (limited to amiodarone in patients with reduced ejection fraction), or catheter ablation, the latter having been shown to be more effective in reducing the risk of HF exacerbation.⁴⁹

HEALTHCARE ORGANISATION

Once the 4 classes of GDMT have been initiated, the doses will require optimisation in the community setting and regular monitoring, with adjustment where necessary to avoid acute exacerbations which may be fatal, and generally require rehospitalisation.

Following discharge from the hospital after an episode of worsening HF, patients enter a vulnerable period, during which transition care programmes are advocated to avoid early HF re-admissions.⁵⁰

A randomized clinical trial is currently underway to document the effectiveness of such programmes.⁵¹

However, a majority of HF patients are not followed-up promptly, when they are still at high risk.⁵²

The dose optimisation phase is crucial and it is recommended that detailed instructions on implementation be provided in the discharge letter for patients going home from hospital.⁵² In the absence of dedicated follow-up, treatment optimisation may not be implemented correctly, and the long-term consequences of this are likely to be more deleterious to prognosis than how the treatments were introduced initially. Unfortunately, many patients discharged from hospital never move on to an optimised treatment regimen due to the inertia of the system.^{11,52-56} Establishing structured post-discharge follow-up is crucial, ideally through a dedicated disease management programme.^{57,58} Trained and dedicated HF nurses are usually the cornerstone of rapid treatment optimisation as they can titrate HF drugs, provide therapeutic education, ensure a personalised contact with the patient and identify early any signs of deterioration. In a recent randomised clinical trial evaluating the role of nurses in up-titrating HF medication, HF nurses achieved higher doses of BB and ACE-Is over a 4-month period than did HF cardiologists, principally because nurses were able to see the patient much more frequently.⁵⁹ In addition, multidisciplinary management involving a dedicated HF nurse has been shown to improve adherence to practice guidelines⁶⁰ and clinical outcomes.⁶¹

Telemedicine programmes can be especially useful to ensure timely modifications of treatment or other interventions should the patient's state deteriorate.⁶²⁻⁶⁴ However, telemedicine may not be appropriate for all patients, notably those with cognitive impairment or poor adherence.

Following an episode of acute decompensation, cardiac rehabilitation involving exercise training associated with psychosocial support and dietary counselling is useful for reducing the risk of rehospitalisation.⁶⁵ Currently, patients are not sufficiently referred to cardiac rehabilitation centres from community care.⁶⁶

In primary care, delays in referral to specialist HF physicians, limited consultation time and lack of communication between health professionals can lead to inadequate implementation of optimal treatment and inappropriate follow-up.⁶⁷ To avoid a silo approach to care of HF patients in the community, multidisciplinary management involving a dedicated HF nurse and both hospital and community cardiologists is essential. Education of healthcare professionals is critical in this respect and provision of online medical expertise could be a powerful way for centres of excellence for HF care to reach out to community healthcare providers.

It is important to emphasise that differences in the organisation of care for patients with HF between regions and countries clearly exist, and these need to be considered when considering how to optimise treatment pathways. However, it is also the responsibility of national decision-makers to ensure that the best quality of care can be offered to all patients and that inequalities in care provision are minimised.

CONCLUSIONS

In this position paper, we propose a pragmatic algorithm for the implementation and optimisation of GDMT for the treatment of HF with reduced ejection fraction. We believe that the sequential

introduction and titration of these '4 pillars of heart failure' within 2 months of an acute exacerbation of pre-existing HF or a recent diagnosis can be achieved routinely in most patients with HF. This needs to be our treatment goal and every effort must be undertaken to achieve it. The algorithm proposed above should help hospital and community physicians achieve this goal in everyday practice.

FUNDING

None.

AUTHORS' CONTRIBUTIONS

NG and FR coordinated the manuscript.

NG, CL, OH, FR drafted parts of the manuscript.

NG, CL, OH, ABG, JIJ, TD, BL, CM, PS and FR provided critical reviewing and editing of the initial draft.

CONFLICTS OF INTEREST

F ROUBILLE reports grants and/or personal fees from Air Liquide, Abbott, Astra Zeneca, Bayer, Boehringer, Novartis, Pfizer, Servier, Vifor; B LEQUEUX reports personal fees from Bayer, Boehringer, Microport, Novartis, Pfizer, Vifor; C LECLERCQ reports personal fees from Novartis, Medtronic, Biotronik, Microport, Abbott; P MEUNE reports grants and/or personal fees from Astra-Zeneca, Novartis, Vifor, Roche Diagnostics; T Damy reports grants and/or personal fees from Novartis, Vifor, RESMED, Pfizer, Alnylam, Ionsis, Akcea, GSK, Prothena; O HANON reports personal fees from Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, Leo Pharma, Medtronic, Novartis, Pfizer, Sanofi, Servier, Vifor; P SABOURET reports personal fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Medtronic, MSD, Novartis, Servier, Sanofi, Vifor Pharma, and have other links of interest with Minerva Cardiology Angiology, Archives of Medical Science, Frontiers in Cardiovascular Medicine. N GIRERD received personal fees from Astra Zeneca, Bayer, Boehringer,

Lilly, Novartis, Pfizer, Vifor, A BAYES-GENIS reports personal fees from Abbott, Novartis, Vifor, Roche Diagnostics, Critical Diagnostics and AstraZeneca, grants, personal fees and non-financial support from Boehringer-Ingelheim. J JANUZZI is a trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received grant support from Applied Therapeutics, Innolife, Novartis Pharmaceuticals, and Abbott Diagnostics; has received consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics; and has participated in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia, and Takeda.

ACKNOWLEDGEMENTS

We thank Adam Doble PhD (SARL Foxymed, France) for helping to prepare the manuscript and acknowledge technical support from Novartis for illustrations.

This manuscript is also endorsed by the Heart Failure Working Group of the French Society of Cardiology.

REFERENCES

1. Metra M, Teerlink JR. Heart failure. *Lancet*. 2017;390:1981-1995.
2. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. *Lancet*. 2019;393:1034-1044.
3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79:e263-e421.
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the

special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2021;42:3599-3726.

5. Bauersachs J. Heart failure drug treatment: the fantastic four. *Eur Heart J.* 2021;42:681-683.
6. Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. *JAMA Cardiol.* 2021;6:743-744.
7. Miller RJH, Howlett JG, Fine NM. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. *Can J Cardiol.* 2021;37:632-643.
8. Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. *Eur J Heart Fail.* 2021;23:882-894.
9. Sharma A, Verma S, Bhatt DL, et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? *JACC Basic Transl Sci.* 2022;7:504-517.
10. Shen L, Jhund PS, Docherty KF, et al. Accelerated and personalized therapy for heart failure with reduced ejection fraction. *Eur Heart J.* 2022;43:2573-2587.
11. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. *Open Heart.* 2021;8:e001585.
12. Fauvel C, Bonnet G, Mullens W, et al. Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey. *Eur J Heart Fail.* 2022. <https://doi.org/10.1002/ejhf.2743>
13. Mullens W, Martens P, Testani JM, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2022;24:603-619.
14. Cautela J, Tartiere JM, Cohen-Solal A, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. *Eur J Heart Fail.* 2020;22:1357-1365.

15. Masarone D, Martucci ML, Errigo V, Pacileo G. The Use of β -Blockers in Heart Failure with Reduced Ejection Fraction. *J Cardiovasc Dev Dis*. 2021;8:101.
16. Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. *Cardiol Clin*. 2014;32:21-32, vii.
17. Docherty KF, McMurray JJV. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. *Int J Cardiol*. 2019;281:179-185.
18. Kubon C, Mistry NB, Grundvold I, Halvorsen S, Kjeldsen SE, Westheim AS. The role of beta-blockers in the treatment of chronic heart failure. *Trends Pharmacol Sci*. 2011;32:206-212.
19. Dyck JRB, Sossalla S, Hamdani N, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. *J Mol Cell Cardiol*. 2022;167:17-31.
20. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition vs enalapril in heart failure. *N Engl J Med*. 2014;371:993-1004.
21. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network Metaanalysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail*. 2022;10:73-84.
22. Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J*. 2021;42:671-680.
23. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019;381:1995-2008.
24. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020;383:1413-1424.
25. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. *Lancet*. 2022;400:1938-1952.

26. Butzner M, Riello RJ, 3rd, Sarocco P, Desai N. Adverse drug effects across patients with heart failure: a systematic review. *Am J Manag Care*. 2022;28:e113-e120.
27. Girerd N. Low Blood Pressure and Managing Drugs in HF: Where Do SGLT2 Inhibitors Stand? *J Am Coll Cardiol*. 2021;78:1349-1351.
28. Qiu M, Ding LL, Zhang M, Zhou HR. Safety of four SGLT2 inhibitors in three chronic diseases: A metaanalysis of large randomized trials of SGLT2 inhibitors. *Diab Vasc Dis Res*. 2021;18:14791641211011016.
29. Mewton N, Girerd N, Boffa JJ, et al. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. *Arch Cardiovasc Dis*. 2020;113:660-670.
30. Girerd N, Seronde MF, Coiro S, et al. Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. *JACC Heart Fail*. 2018;6:273-285.
31. Riccardi M, Sammartino AM, Piepoli M, et al. Heart failure: an update from the last years and a look at the near future. *ESC Heart Fail*. 2022;9:3667-3693.
32. Jobs A, Abdin A, de Waha-Thiele S, et al. Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a metaanalysis of early studies. *Clin Res Cardiol*. 2019;108:1240-1248.
33. Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. *Eur J Heart Fail*. 2019;21:337-341.
34. Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. *Adv Ther*. 2022;39:148-164.
35. Książczyk M, Lelonek M. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. *Heart Fail Rev*. 2020;25:393-402.

36. Rosano GMC, Allen LA, Abidin A, et al. Drug Layering in Heart Failure: Phenotype-Guided Initiation. *JACC Heart Fail.* 2021;9:775-783.
37. Boureau AS, Annweiler C, Belmin J, et al. Practical management of frailty in older patients with heart failure. Statement from a panel of multidisciplinary experts on behalf the Heart Failure Working Group of the French Society of Cardiology and on behalf French Society of Geriatrics and Gerontology. *ESC Heart Fail.* 2022;9:4053-4063.
38. Meldon SW, Mion LC, Palmer RM, et al. A brief risk-stratification tool to predict repeat emergency department visits and hospitalizations in older patients discharged from the emergency department. *Acad Emerg Med.* 2003;10:224-32.
39. Bouilly C, Vidal JS, Guibert E, et al. National survey on the management of heart failure in individuals over 80 years of age in French geriatric care units. *BMC Geriatr.* 2019;19:204.
40. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: A systematic review and metaanalysis. *Int J Cardiol.* 2017;236:283-289.
41. Yang X, Lupón J, Vidán MT, et al. Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Metaanalysis. *J Am Heart Assoc.* 2018;7:e008251.
42. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. *J Nutr Health Aging.* 2008;12:29-37.
43. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *Cmaj.* 2005;173:489-495.
44. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56:M146-56.
45. Damy T, Chouihed T, Delarche N, et al. Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper. *J Clin Med.* 2021;10:3519.
46. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. *Nat Rev Cardiol.* 2016;13:131-147.

47. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Vs Reduced Ejection Fraction. *Circulation*. 2016;133:484-492.
48. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation*. 2003;107:2920-2925.
49. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. *N Engl J Med*. 2018;378:417-427.
50. Comín-Colet J, Enjuanes C, Lupón J, Cainzos-Achirica M, Badosa N, Verdú JM. Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization. *Rev Esp Cardiol*. 2016;69:951-961.
51. Duflos C, Labarre JP, Ologeanu R, et al. PRADOC: a trial on the efficiency of a transition care management plan for hospitalized patients with heart failure in France. *ESC Heart Fail*. 2021;8:1649-1655.
52. Girerd N, Von Hunolstein JJ, Pellicori P, et al. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. *ESC Heart Fail*. 2022;9:2063-2069.
53. Berthelot E, Eicher J-C, M S, et al. Medical Inertia in the Optimization of Heart Failure Treatment after Discharge and its Relationship to Outcome. *Health Care : Current Reviews*. 2018;06:1.
54. Greene SJ, Fonarow GC, DeVore AD, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019;73:2365-2383.
55. Logeart D, Isnard R, Resche-Rigon M, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. *Eur J Heart Fail*. 2013;15:465-476.
56. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J*. 2006;27:2725-2736.

57. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol*. 2004;44:810-819.
58. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. *The Cochrane database of systematic reviews*. 2019;1:CD002752.
59. Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, et al. Noninferiority of heart failure nurse titration vs heart failure cardiologist titration. ETIFIC multicenter randomized trial. *Rev Esp Cardiol*. 2021;74:533-543.
60. Shanbhag D, Graham ID, Harlos K, et al. Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. *BMJ Open*. 2018;8:e017765.
61. Gandhi S, Mosleh W, Sharma UC, Demers C, Farkouh ME, Schwalm JD. Multidisciplinary Heart Failure Clinics Are Associated With Lower Heart Failure Hospitalization and Mortality: Systematic Review and Metaanalysis. *Can J Cardiol*. 2017;33:1237-1244.
62. Anker SD, Koehler F, Abraham WT. Telemedicine and remote management of patients with heart failure. *Lancet*. 2011;378:731-739.
63. Galinier M, Roubille F, Berdague P, et al. Telemonitoring vs standard care in heart failure: a randomised multicentre trial. *Eur J Heart Fail*. 2020;22:985-994.
64. Sabatier R, Legallois D, Jodar M, et al. Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality. *ESC Heart Fail*. 2022;9:2886-2898.
65. Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. *Nat Rev Cardiol*. 2022;19:180-194.
66. Giuliano C, Vicendese D, Vogrin S, et al. Predictors of Referral to Cardiac Rehabilitation in Patients following Hospitalisation with Heart Failure: A Multivariate Regression Analysis. *J Clin Med*. 2022;11:1232.

67. Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. *BMJ Open*. 2014;4:e003866.


FIGURES

Figure 1. Proposed treatment algorithm for patients with heart failure.

1. In patients with an eGFR between 30 and 40 ml/min/1.73m², kidney function and serum electrolytes should be monitored more closely.
2. Particular attention should be paid to regular monitoring of serum potassium in this group.
3. ARNIs are to be preferred to ACEIs, as this will allow the treatment to be optimised most rapidly. However, ACEIs can be used as an alternative, notably if ARNIs are contra-indicated. A ¼ dose of the ARNI sacubitril/valsartan corresponds to 24/26 mg *bid* and a ½ dose to 49/51 mg *bid*.
4. In patients with ventricular tachycardia or premature ventricular contractions, a BB should be preferred to an ACEI as a first step. Caution should be exerted in patients with either very low BP or clinical instability.
5. Titration should not be considered definitive, and medication should be reassessed at each follow-up visit in function of the general medical condition of the patient. Even in patients whose ejection fraction improves after treatment, guideline-directed medical therapy should be pursued.

ACEI, angiotensin-converting enzyme inhibitor; AE, adverse events; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blockers; BP, blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart rate; MRA, mineralocorticoid receptor antagonist; SGLT2I, sodium-glucose like transporter type 2 inhibitor; VT, ventricular tachycardia.

PATIENTS WITH HEART FAILURE




TITRATION OF THE FOUR HF MEDICATIONS ⑤

- UP-TITRATE EVERY 1 - 2 WEEKS until maximum tolerated dose is reached.
- INCREASE 1 - 2 MEDICATIONS AT THE SAME TIME (exceptionally 3 for patients with good renal function and sufficiently high blood pressure).
- REDUCE DIURETICS whenever possible.
- CHECK RENAL FUNCTION and SERUM POTASSIUM between each titration visit.
- CONSIDER TELEMONITORING for treatment optimisation.

Perform blood monitoring within SEVEN days of EACH drug introduction or escalation step.

Monitor heart rate and blood pressure following EACH medication change.

Figure 2. Central illustration. An algorithm is proposed on how to introduce and optimise the 4 GDMT medications based on factors that influence drug tolerability, giving recommendations for monitoring and titration to achieve optimal dosing within 30 days. ACEI, angiotensin-converting enzyme inhibitor; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blockers; BP, blood pressure; HR, heart rate; MRA, mineralocorticoid receptor antagonist; SGLT2I, sodium-glucose like



transporter type 2 inhibitor.

Figure 3. Proposed treatment algorithm for patients aged >75 years with heart failure.

1. In patients with an eGFR between 30 and 40 ml/min/1.73m², kidney function and serum electrolytes should be monitored more closely.
2. ARNIs are to be preferred to ACEIs, as this will allow the treatment to be optimised most rapidly. However, ACEIs can be used as an alternative, notably if ARNIs are contra-indicated. A ¼ dose of the ARNI sacubitril/valsartan corresponds to 24/26 mg *bid* and a ½ dose to 49/51 mg *bid*.
3. Titration should not be considered definitive, and medication should be reassessed at each follow-up visit in function of the general medical condition of the patient. Even in patients whose ejection fraction improves after treatment, guideline-directed medical therapy should be pursued.

ACEI, angiotensin-converting enzyme inhibitor; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blockers; CGA, Comprehensive Geriatric Assessment; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart rate; MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; SGLT2I, sodium-glucose like transporter type 2 inhibitor; TRST, Triage Risk Screening Tool; VT, ventricular tachycardia.

